euro adhoc: LION bioscience AG
Mergers - Acquisitions - Takeovers
Ad-hoc release LION bioscience confirms take-over bid of Hopp family (DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG)

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Heidelberg, July 5, 2006 - LION bioscience received today the information  that two investment-companies of the Hopp family, DH-Capital GmbH &  Co.  KG  und  OH Beteiligungen GmbH & Co. KG, will make a voluntary bid to acquire all shares  of LION bioscience AG at a price of EUR 1.82 per share.

This decision is to be seen before the background  of  the  contract signed  by LION bioscience AG today to acquire SYGNIS Bioscience mbH &  Co.  KG,  owned  by the majority of the investment-company of the Hopp familiy. In this transaction, LION bioscience AG will pay in shares using the  authorized capital of the company. Furthermore, as both investment companies of the Hopp family  committed  further

@@start.t2@@capital inflow into LION bioscience AG, it is to  be  expected  that  they  will
further increase their stake in LION.
For further information, please contact:
|Peter Willinger                                      |Dr. Franz-Werner Haas                    |
|Chief Executive Officer                         |General Counsel                              |
|Tel: +49 (0) 6221-4038 293                    |Tel: +49 (0) 6221-4038 340            |
|Email:                                                    |Email:                                            |
|        |franz.werner.haas@lionbioscience.c|
|                                                              |om                                                  |
|                                                              |                                                      |
Except for the historical information contained herein, the  matters  set  forth
in this press release are forward looking. These forward-looking statements  may
include  projections,  assumptions,  estimates,  targets,  and  descriptions  of
future events. Such statements are based on currently available information  and
on LION's current expectations as to future events that  may  not  prove  to  be
accurate. These statements are not guarantees of future performance and  involve@@end@@

risks and uncertainties that are difficult to predict. Many factors could  cause the actual results,  performance  or  achievements  of LION  to  be  materially different from those that may be projected, expected,  targeted,  expressed  or implied by such statements. All roll-out plans and future dates with respect  to completion of development and market release of LION products are  target  dates only based on the company's current planning and may change in the future.  Any delays in the current product release schedule will have a  materially  adverse effect on the company's targets for fiscal year. ###

@@start.t3@@end of announcement                                                 euro adhoc 05.07.2006 21:40:19

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar:

Further inquiry note:
Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              New York / ADR
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: